SAMABRIVA

SAMABRIVA is a biotechnology startup focused on precision biomanufacturing of complex biomolecules. The company's slogan "Precision biomanufacturing of complex biomolecules" perfectly encapsulates their mission. Founded in 2011 and headquartered in France, SAMABRIVA Biotechnology has made remarkable strides in the Biotechnology and Health Care industries. SAMABRIVA is pioneering a novel method for producing biopharmaceuticals, chemicals, and biotech products by harnessing the power of plants. The company's innovative approach involves developing and cultivating high-yield plant clones in large-scale bioreactors. This methodology offers a flexible platform that combines the advantages of plant-based systems with traditional biomanufacturing techniques, enabling the production of high-value products more efficiently than conventional methods. Notably, SAMABRIVA recently secured a significant €4.00M Series A investment from Noshaq, a testament to the confidence and interest this promising startup has garnered from investors. This substantial investment was received on 12 December 2023, underlining the growing potential and attractiveness of SAMABRIVA's innovative biomanufacturing approach.